Encysive launches Thelin in Spain

Encysive received European marketing authorization for Thelin in August 2006. Thelin is the first selective endoThelin A receptor antagonist, and the first once-daily oral treatment available for patients with pulmonary arterial hypertension (PAH).

The European Commission's centralized licensing procedure permits Encysive to market Thelin in all 27 member states of the EU. Thelin will be launched in successive EU member states as local government approval for reimbursement is obtained.

Thelin is used for improving exercise capacity in PAH patients classified as World Health Organization functional class III. Efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease.

George Cole, president and CEO, said: “We are pleased to have Thelin now available to patients in Spain, through partnership with Praxis. We are able to immediately begin selling Thelin in Spain without the need to invest in a dedicated sales and marketing infrastructure.”